title: Impairment of quality of life in patients with antiphospholipid syndrome.
abstract: OBJECTIVE
  Health-related quality of life (HRQoL) has not been fully explored in antiphospholipid syndrome (APS); therefore, we compared HRQoL between APS patients and the general population and assessed the impact of thromboembolic history.
  
  
  METHODS
  HRQoL was measured in a multicentre cohort study by the Medical Outcomes Study Short-Form 36 (MOS-SF-36) questionnaire. HRQoL scores were compared to the French general population norms. Factors significantly associated with an impaired HRQoL were identified.
  
  
  RESULTS
  A total of 115 patients with aPL and/or systemic lupus erythematosus (SLE) were included (mean age 42.7 ± 14.1 years old, 86 women). In 53 patients APS was diagnosed. Compared to general population norms, patients with APS had an impaired HRQoL. SLE-associated APS patients had the worst HRQoL scores (physical component summary (PCS)=40.8 ± 10.6; mental component summary (MCS)=40.6 ± 16.5) in comparison with SLE or aPL patients without thromboembolic history. In APS patients, history of arterial thrombosis significantly impaired HRQoL (PCS score: 42.2 ± 9.4 vs 49.2 ± 8.5; MCS score: 33.9 ± 13.7 vs 44.6 ± 10.3).
  
  
  CONCLUSIONS
  Compared to the general population, APS patients experienced a lower HRQoL. In these patients, a history of arterial thrombosis significantly impaired HRQoL. Therefore, measurements of HRQoL should be included in APS patient management to assess the burden of the disease from a patient's perspective and to provide patients with the support they need.
authors: CHU de Nancy, Vascular Medicine Division and Regional Competence Centre for Systemic and Autoimmune Diseases, Nancy, France Inserm, UMR_S 1116, Nancy, France Université de Lorraine, Nancy, France.
authors: S
authors: S
authors: Zuily
authors: Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France Inserm, CIC-EC CIE6, Nancy, France CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, France CHU de Nancy, Rheumatology Department, Nancy, France.
authors: A-C
authors: AC
authors: Rat
authors: Inserm, UMR_S 1116, Nancy, France Université de Lorraine, Nancy, France CHU de Nancy, Contrat d'interface, Nancy, France.
authors: V
authors: V
authors: Regnault
authors: Université de Lorraine, Nancy, France CHU de Nancy, Orphan Disease Unit, Nancy, France.
authors: P
authors: P
authors: Kaminsky
authors: CHU de Saint Etienne, Clinical Pharmacology Unit and EA 3065, Saint-Etienne, France.
authors: P
authors: P
authors: Mismetti
authors: CHU de Lyon, Department of Internal Medicine, Lyon, France.
authors: J
authors: J
authors: Ninet
authors: Colmar Hospital, Department of Internal Medicine, Colmar, France.
authors: N
authors: N
authors: Baillet
authors: CHU de Besançon, Internal Medicine and Clinical Immunology Department, Besançon, France.
authors: N
authors: N
authors: Magy-Bertrand
authors: CHU de Strasbourg, Internal Medicine and Clinical Immunology Department, Strasbourg, France.
authors: J-L
authors: JL
authors: Pasquali
authors: CHRU de Lille, Department of Internal Medicine, Lille, France.
authors: M
authors: M
authors: Lambert
authors: CHU de Brest, Department of Internal Medicine and Chest Diseases and EA 3878, Brest, France.
authors: E
authors: E
authors: Pasquier
authors: CHU de Dijon, Internal Medicine and Clinical Immunology Department, Dijon, France.
authors: B
authors: B
authors: Lorcerie
authors: Université de Lorraine, Nancy, France University Hospitals of Geneva, Division of Haematology, Geneva, Switzerland (T.L. current address).
authors: T
authors: T
authors: Lecompte
authors: Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, France.
authors: F
authors: F
authors: Guillemin
authors: CHU de Nancy, Vascular Medicine Division and Regional Competence Centre for Systemic and Autoimmune Diseases, Nancy, France Inserm, UMR_S 1116, Nancy, France Université de Lorraine, Nancy, France d.wahl@chu-nancy.fr.
authors: D
authors: D
authors: Wahl
mesh_terms: D000328:Adult; D016736:Antiphospholipid Syndrome / Q000503:physiopathology* / Q000523:psychology; D015331:Cohort Studies; D005260:Female; D006304:Health Status; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000503:physiopathology / Q000523:psychology; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011788:Quality of Life; D012307:Risk Factors; D011795:Surveys and Questionnaires; D013927:Thrombosis / Q000503:physiopathology
keywords: Antiphospholipid syndrome; MOS-SF-36; arterial thrombosis; quality of life; systemic lupus erythematosus